QuidelOrtho (QDEL)
(Delayed Data from NSDQ)
$44.85 USD
+0.73 (1.65%)
Updated Sep 11, 2024 03:59 PM ET
After-Market: $45.07 +0.22 (0.49%) 5:14 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$44.85 USD
+0.73 (1.65%)
Updated Sep 11, 2024 03:59 PM ET
After-Market: $45.07 +0.22 (0.49%) 5:14 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
Zacks News
Omeros (OMER) in Focus: Stock Moves 8.5% Higher
by Zacks Equity Research
Omeros (OMER) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Top Ranked Growth Stocks to Buy for December 2nd
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, December 2nd.
Sol-Gel Technologies (SLGL) Looks Good: Stock Adds 8.8% in Session
by Zacks Equity Research
Sol-Gel Technologies (SLGL) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Quidel (QDEL) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Quidel (QDEL) possesses solid growth attributes, which could help it handily outperform the market.
5 Best Momentum Picks Using Driehaus Strategy
by Nitish Marwah
After a detailed study of Driehaus' strategy, AAII concluded that it mainly focuses on strong earnings growth rates and impressive prospects to pick potential outperformers.
Has Quidel (QDEL) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (QDEL) Outperforming Other Medical Stocks This Year?
10 Stocks That Deserve Thanks in Pandemic-Ravaged 2020
by Sweta Killa
While the gains are broad based, we have highlighted 10 stocks - APPS, OMI, EXPI, TUP, STKL, CALX, VSTO, CMBM, QDEL and AVNW - that have been on the forefront of the rally this year.
Encompass Health (EHC) Continues to Bolster Presence in Ohio
by Zacks Equity Research
Encompass Health (EHC) continues to expand in Ohio via inauguration of the inpatient rehabilitation hospital in order to offer improved health services in the state.
Hologic, Disney, Quidel, Alibaba, JD.com and Tencent highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Hologic, Disney, Quidel, Alibaba, JD.com and Tencent highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Hologic (HOLX)
by Kevin Cook
This leader in women's health diagnostics is ramping high double-digit growth on COVID testing
Centene (CNC) Marketplace Product Undergoes Technology Upgrade
by Zacks Equity Research
Centene's (CNC) Marketplace product - Ambetter undertakes technology improvements for benefiting members and new enrollees.
Buy These 3 Momentum Anomaly Stocks to Maximize Your Returns
by Zacks Equity Research
Hologic (HOLX), Logitech (LOGI) and Quidel (QDEL) are currently witnessing a short-term pullback in price. So make sure you're taking full advantage of it.
Is Quidel (QDEL) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (QDEL) Outperforming Other Medical Stocks This Year?
Should You Invest in the SPDR SP Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Wall Street Jumps Without a Blue or Red Wave: What Awaits?
by Nalak Das
It will be a better strategy to invest in Zacks Rank #1 (Strong Buy) stocks with long-term growth potential like FedEx (FDX), Whirlpool (WHR), The Boston Beer (SAM), Lennar (LEN), Quidel (QDEL), PerkinElmer (PKI) and Newmont (NEM).
Quidel (QDEL) Q3 Earnings Beat Estimates
by Zacks Equity Research
Quidel (QDEL) delivered earnings and revenue surprises of 26.20% and -0.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Can Diagnostics Aid Hologic (HOLX) Q4 Sales Amid Coronavirus?
by Zacks Equity Research
Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the fourth quarter of fiscal 2020 amid the coronavirus-led economic doldrums.
Owens & Minor (OMI) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Owens & Minor's (OMI) PPE sales are likely to have maintained its momentum during Q3, thus driving the top line.
STERIS (STE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Within Life Sciences, STERIS (STE) might have registered benefit from pharma customers on growing vaccines and biologics businesses in Q2.
DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) third-quarter results benefit from solid segmental performance.
Quidel (QDEL) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Quidel's (QDEL) fiscal third-quarter results are likely to reflect solid show by Subscriptions and Managed Services segments.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q3.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q4
by Zacks Equity Research
Varian's (VAR) receipt of 10 Ethos orders in Q4 instills optimism
Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q3.
Quidel (QDEL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q3.